London · Delayed Price · Currency is GBP · Price in USD KALA BIO Statistics
Total Valuation
KALA BIO has a market cap or net worth of GBP 7.53 million. The enterprise value is 14.03 million.
| Market Cap | 7.53M |
| Enterprise Value | 14.03M |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 28.25M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +86.46% |
| Shares Change (QoQ) | +8.13% |
| Owned by Insiders (%) | 0.31% |
| Owned by Institutions (%) | 19.07% |
| Float | 28.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -1.17 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.53 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.59 |
Financial Position
The company has a current ratio of 0.75
| Current Ratio | 0.75 |
| Quick Ratio | 0.65 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.93 |
| Interest Coverage | -9.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -65.81% |
| Return on Invested Capital (ROIC) | -79.87% |
| Return on Capital Employed (ROCE) | 551.34% |
| Weighted Average Cost of Capital (WACC) | 6.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -701,672 |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.10% in the last 52 weeks. The beta is -2.45, so KALA BIO's price volatility has been lower than the market average.
| Beta (5Y) | -2.45 |
| 52-Week Price Change | -96.10% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 4.44 |
| Relative Strength Index (RSI) | 32.64 |
| Average Volume (20 Days) | 22,987 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -30.98M |
| Pretax Income | -26.66M |
| Net Income | -26.66M |
| EBITDA | -30.73M |
| EBIT | -30.98M |
| Earnings Per Share (EPS) | -4.33 |
Balance Sheet
The company has 15.69 million in cash and 22.28 million in debt, with a net cash position of -6.58 million.
| Cash & Cash Equivalents | 15.69M |
| Total Debt | 22.28M |
| Net Cash | -6.58M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -6.45M |
| Book Value Per Share | -0.87 |
| Working Capital | -6.17M |
Cash Flow
In the last 12 months, operating cash flow was -23.83 million and capital expenditures -62,491, giving a free cash flow of -23.89 million.
| Operating Cash Flow | -23.83M |
| Capital Expenditures | -62,491 |
| Free Cash Flow | -23.89M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KALA BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -86.46% |
| Shareholder Yield | -86.46% |
| Earnings Yield | -353.90% |
| FCF Yield | -317.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 21, 2022. It was a reverse split with a ratio of 0.02.
| Last Split Date | Oct 21, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.02 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |